UNICA IRIS Institutional Research Information System

PRETTA, ANDREA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 34.491
NA - Nord America 2.401
AS - Asia 1.592
SA - Sud America 268
AF - Africa 40
OC - Oceania 6
Continente sconosciuto - Info sul continente non disponibili 1
Totale 38.799
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 33.723
US - Stati Uniti d'America 2.304
SG - Singapore 617
CN - Cina 555
BR - Brasile 217
SE - Svezia 217
DE - Germania 137
VN - Vietnam 113
GB - Regno Unito 81
FR - Francia 69
IN - India 63
NL - Olanda 62
FI - Finlandia 60
HK - Hong Kong 51
CA - Canada 50
KR - Corea 46
MX - Messico 32
PL - Polonia 25
AT - Austria 21
ES - Italia 21
TR - Turchia 20
IE - Irlanda 17
IQ - Iraq 15
EC - Ecuador 14
IR - Iran 14
JP - Giappone 14
ZA - Sudafrica 13
AE - Emirati Arabi Uniti 12
BD - Bangladesh 12
AR - Argentina 11
BE - Belgio 11
VE - Venezuela 9
PK - Pakistan 8
RU - Federazione Russa 8
UZ - Uzbekistan 7
AU - Australia 6
LT - Lituania 6
MA - Marocco 6
UA - Ucraina 6
CO - Colombia 5
ID - Indonesia 5
TH - Thailandia 5
GR - Grecia 4
PH - Filippine 4
PY - Paraguay 4
SA - Arabia Saudita 4
BZ - Belize 3
CL - Cile 3
DZ - Algeria 3
KE - Kenya 3
KG - Kirghizistan 3
NP - Nepal 3
PE - Perù 3
PT - Portogallo 3
TN - Tunisia 3
TW - Taiwan 3
AM - Armenia 2
AZ - Azerbaigian 2
BB - Barbados 2
CH - Svizzera 2
CR - Costa Rica 2
CZ - Repubblica Ceca 2
GA - Gabon 2
IL - Israele 2
JM - Giamaica 2
KZ - Kazakistan 2
LU - Lussemburgo 2
LV - Lettonia 2
MN - Mongolia 2
MU - Mauritius 2
NG - Nigeria 2
NO - Norvegia 2
PA - Panama 2
RS - Serbia 2
SC - Seychelles 2
SK - Slovacchia (Repubblica Slovacca) 2
TT - Trinidad e Tobago 2
AL - Albania 1
BG - Bulgaria 1
BH - Bahrain 1
BJ - Benin 1
BO - Bolivia 1
CI - Costa d'Avorio 1
DM - Dominica 1
EG - Egitto 1
ET - Etiopia 1
HN - Honduras 1
HR - Croazia 1
HU - Ungheria 1
KH - Cambogia 1
LB - Libano 1
LK - Sri Lanka 1
MK - Macedonia 1
MO - Macao, regione amministrativa speciale della Cina 1
MY - Malesia 1
OM - Oman 1
PS - Palestinian Territory 1
RO - Romania 1
UY - Uruguay 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 38.799
Salva come PNG Salva come JPEG
Città #
Cagliari 31.574
Uta 1.832
Dallas 521
Ashburn 374
Singapore 335
Boardman 164
Beijing 125
Nyköping 104
Los Angeles 99
Chandler 89
Fairfield 85
Hefei 76
New York 71
Santa Clara 63
Shanghai 49
Hong Kong 48
Seoul 45
Amsterdam 44
Rome 44
Ho Chi Minh City 43
Houston 39
Seattle 36
Florence 35
Munich 35
The Dalles 34
Wilmington 33
Nuremberg 31
Helsinki 30
Redondo Beach 30
Boston 28
Cambridge 28
Frankfurt am Main 28
Woodbridge 26
São Paulo 22
Buffalo 21
Pune 21
Montreal 20
Guangzhou 19
Warsaw 19
San Diego 18
Stockholm 18
Toronto 16
Chennai 15
Chicago 15
Hanoi 15
London 15
Turku 15
Dublin 14
Düsseldorf 14
Lappeenranta 14
Mexico City 14
Poplar 14
Denver 13
Milan 13
Shenzhen 13
Orem 11
Selargius 11
Johannesburg 10
Vienna 10
Manchester 9
Rio de Janeiro 9
Brooklyn 8
Dong Ket 8
Paris 8
Roubaix 8
Wuhan 8
Ankara 7
Atlanta 7
Brussels 7
Dubai 7
Haiphong 7
Istanbul 7
Salt Lake City 7
Tashkent 7
Tokyo 7
Zhengzhou 7
Baghdad 6
Querétaro 6
Quito 6
San Francisco 6
Tianjin 6
Bexley 5
Casablanca 5
Clifton 5
Forlì 5
Jacksonville 5
Lauterbourg 5
Menlo Park 5
New Delhi 5
Olbia 5
Phoenix 5
Portsmouth 5
Sassari 5
Tehran 5
Ann Arbor 4
Belo Horizonte 4
Biên Hòa 4
Campinas 4
Charlotte 4
Dearborn 4
Totale 36.845
Salva come PNG Salva come JPEG
Nome #
BRAF-mutant colorectal cancer, a different breed evolving 3.211
Molecular-biology-driven treatment for metastatic colorectal cancer 2.716
Colorectal cancer early detection in stool samples tracing CPG islands methylation alterations affecting gene expression 2.325
New therapeutic targets in pancreatic cancer 1.591
Immunotherapy and Cancer: The Multi-Omics Perspective 1.556
Why precision medicine should be applied across the continuum of care for metastatic colorectal cancer patients? 1.489
Hepatocellular carcinoma and microbiota: Implications for clinical management and treatment 1.307
Molecular-driven treatment for biliary tract cancer: the promising turning point 1.183
How to improve metastatic pancreatic ductal adenocarcinoma patients' selection: Between clinical trials and the real-world 1.136
Colorectal cancer promoter methylation alteration affects the expression of glutamate ionotropic receptor AMPA type subunit 4 alternative isoforms potentially relevant in colon tissue 1.008
CDX-2 expression correlates with clinical outcomes in MSI-H metastatic colorectal cancer patients receiving immune checkpoint inhibitors 1.005
Neoadjuvant chemo-radiotherapy response in patients affected by mismatch repair deficient (dMMR) locally advanced rectal cancer 945
Retrospective Comparative Analysis of KRAS G12C vs. Other KRAS Mutations in mCRC Patients Treated With First-Line Chemotherapy Doublet + Bevacizumab 909
Liquid Biopsy-Driven Cetuximab Rechallenge Strategy in Molecularly Selected Metastatic Colorectal Cancer Patients 903
Balance between the stem cell marker CD44 and CDX2 expression in colorectal cancer 901
Introducing immunotherapy for advanced hepatocellular carcinoma patients: Too early or too fast? 899
Impact of Aspirin on clinical outcome in advanced HCC patients receiving sorafenib and regorafenib 864
The Role of p53 Expression in Patients with RAS/BRAF Wild-Type Metastatic Colorectal Cancer Receiving Irinotecan and Cetuximab as Later Line Treatment 814
Corrigendum: Why precision medicine should be applied across the continuum of care for metastatic colorectal cancer patients 743
New Horizons in Metastatic Colorectal Cancer: Prognostic Role of CD44 Expression 711
Uncovering key targets of success for immunotherapy in pancreatic cancer 679
Effect of Cancer-Related Cachexia and Associated Changes in Nutritional Status, Inflammatory Status, and Muscle Mass on Immunotherapy Efficacy and Survival in Patients with Advanced Non-Small Cell Lung Cancer 672
Circulating tumour DNA in gastrointestinal cancer in clinical practice: Just a dream or maybe not? 668
The role of nanoliposomal irinotecan plus fluorouracil/leucovorin in the continuum of care of patients with metastatic pancreatic ductal adenocarcinoma 635
Retrospective survival analysis in patients with metastatic pancreatic ductal adenocarcinoma with insulin-treated type 2 diabetes mellitus 623
BRCA-mutant pancreatic ductal adenocarcinoma 583
Mismatch Repair system protein deficiency as a resistance factor for locally advanced rectal adenocarcinoma patients receiving neoadjuvant chemo-radiotherapy 569
Immune Checkpoint Inhibitors in the Treatment of HCC 551
Next-generation sequencing analysis of cholangiocarcinoma identifies distinct IDH1-mutated clusters 543
Prediction of Response to Anti-Angiogenic Treatment for Advanced Colorectal Cancer Patients: From Biological Factors to Functional Imaging 529
Influence of antidiabetic drugs on glucose metabolism and immune response in patients with metastatic pancreatic ductal adenocarcinoma receiving gemcitabine plus nab-paclitaxel as first-line treatment 513
Primary adrenal insufficiency induced by immune checkpoint inhibitors: Biological, clinical, and radiological aspects 480
Understanding the user's point of view: when the doctor gets sick with cancer and seeks help 436
Clinical Outcomes After Progression on First-Line Therapies in IDH1 Mutated Versus Wild-Type Intrahepatic Cholangiocarcinoma Patients 410
Patients with early-onset metastatic colorectal cancer as an emerging distinctive clinical and molecular phenomenon 404
CDK4/6 inhibition in hormone receptor-positive/HER2-negative breast cancer: Biological and clinical aspects 313
Molecular profile and its clinical impact of IDH1 mutated versus IDH1 wild type intrahepatic cholangiocarcinoma 301
Fibroblast growth factor receptors as targets for anticancer therapy in cholangiocarcinomas and urothelial carcinomas 296
Clinical score for colorectal cancer patients with lung-limited metastases undergoing surgical resection: Meta-Lung Score 252
Artificial Intelligence Models for the Detection of Microsatellite Instability from Whole-Slide Imaging of Colorectal Cancer 240
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real-world data 238
Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter Study 221
CD44: A New Prognostic Marker in Colorectal Cancer? 211
A new prognostic score for biliary tract cancer: a multicenter experience 192
Mismatch repair proteins (MMR) expression as predictive factor in locally advanced rectal cancer 174
Thyroid dysfunction and immune checkpoint inhibitors: Effect on survival in elderly patients 151
Fentanyl pectin nasal spray for breakthrough cancer pain treatment: a single center experience 150
Medical management of malignant bowel obstruction: our center experience 149
Guideline Application in Real world: multi-Institutional Based survey of Adjuvant and first-Line pancreatic Ductal adenocarcinoma treatment in Italy. Primary analysis of the GARIBALDI survey 148
Early taxane exposure and neurotoxicity in breast cancer patients 148
Overall survival and progression-free survival in metastatic colorectal cancer patients with concomitant RAS and BRAF mutations: a single center experience 147
Early-onset colorectal cancer patients exhibit a distinct molecular fingerprint: insights from a large-scale NGS study of 1209 patients 132
Leptin as a surrogate immune-metabolic marker to predict impact of anti-cachectic therapy: results of a prospective randomized trial in multiple solid tumors 124
Navigating the Landscape of Liquid Biopsy in Colorectal Cancer: Current Insights and Future Directions 119
Cancer-associated fibroblasts (CAFs) and plaque-associated fibroblasts (PAFs): Unraveling the cellular crossroads of atherosclerosis and cancer 114
Exercise Prescription in Cardio-Oncology 73
Clinical characteristics and outcomes in patients with early-onset locally advanced rectal cancer 68
Influence of levothyroxine concomitant treatment on treatment responses and outcomes in patients with metastatic colorectal adenocarcinoma 66
The interconnection between cellular metabolism and lymphocyte activation as a prognostic factor in patients affected by metastatic pancreatic ductal adenocarcinoma treated with gemcitabine and nab-paclitaxel as first line 58
Lymphocyte to monocyte ratio in metastatic pancreatic ductal adenocarcinoma as a prognostic factor and its potential role in identifying a subset of patients with a favorable response to therapy 56
Early onset metastatic colorectal cancer: Clinical-prognostic characteristics and correlation to molecular profile 54
The impact of surgical resection in early onset colorectal cancer patients with liver limited disease 52
Comparison between different therapeutic sequences in patients affected by metastatic pancreatic ductal adenocarcinoma 51
The correlation between L1CAM expression and outcomes in patients with metastatic colorectal cancer treated with first-line chemotherapy 50
Clinical and molecular features of early-onset metastatic pancreatic cancer and their impact on therapeutic sequences: A multicenter study 46
The role of metastasectomy in patients with early onset metastatic colorectal cancer 43
The impact of the fetal exposome as a predictor of cancer risk in childhood and adulthood. Aberrant epigenetic events occurring during gestation: May they trigger fetal programming of cancer risk later in life? 43
Early onset metastatic colorectal cancer patients as a distinctive clinical and molecular phenomenon 19
Treatment compliance in early-stage anal cancer 6
Prognostic Value of the Pace of Tumor Progression as Assessed by Serial 18F-FDG PET/CT Scan and Liquid Biopsy in Refractory Colorectal Cancer: The CORIOLAN Trial 6
Feasibility and clinical impact of routine molecular testing of gastrointestinal cancers at a tertiary centre with a multi-gene, tumor-agnostic, next generation sequencing panel 3
Total neoadjuvant therapy for rectal cancer: Making sense of the results from the RAPIDO and PRODIGE 23 trials 3
Abstract 28: Prognostic value of baseline and early changes of circulating cell-free (cf)DNA in the neoadjuvant setting of early stage colon cancer (CC) 2
Rationale and design of REGINA, a phase II trial of neoadjuvant regorafenib, nivolumab, and short-course radiotherapy in stage II and III rectal cancer 2
Sex and Regorafenib Toxicity in Refractory Colorectal Cancer: Safety Analysis of the RegARd-C Trial 2
MOMENTUM: A Phase I Trial Investigating 2 Schedules of Capecitabine With Aflibercept in Patients With Gastrointestinal and Breast Cancer 1
Totale 39.035
Salva come PNG Salva come JPEG
Categoria #
all - tutte 58.170
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 58.170
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.869 0 0 0 0 0 530 186 310 140 289 252 162
2021/20222.042 127 87 24 97 119 135 96 187 170 229 334 437
2022/20235.037 400 643 563 372 376 438 226 391 428 528 441 231
2023/20245.556 261 184 185 280 429 859 960 424 371 351 576 676
2024/202517.561 5.035 5.672 1.555 1.659 786 1.105 805 104 197 185 149 309
2025/20263.262 499 410 791 646 535 381 0 0 0 0 0 0
Totale 39.035